CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.17933 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2024. Written by Hye Won Lee and 7 co-authors. Institution: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Major MEDLINE topics: Carcinoma, Hepatocellular, Hepatitis B, Chronic, Liver Neoplasms, Hepatitis B Surface Antigens. Cited 15 times so far (Crossref); 23 references. Funded by: National Evidence-based Healthcare Collaborating Agency, National R & D Program for Cancer Control, National Research Foundation of Korea.
Abstract (original language)
Background
Risk of hepatocellular carcinoma (HCC) persists after hepatitis B surface antigen (HBsAg) seroclearance in patients with chronic hepatitis B (CHB).
Aims
To identify risk factors and construct a predictive model for HCC development.
Methods
We retrospectively analysed patients with CHB with HBsAg seroclearance. Primary outcome was HCC development. Factors identified from a multivariate Cox model in the training cohort, consisting of 3476 patients from two Korean hospitals, were used to construct the prediction model. External validation was performed using data from 5255 patients in Hong Kong.
Results
In the training cohort, HCC occurred in 102 patients during 24,019 person‐years of observation (0.43%/year). Risk scores were assigned to cirrhosis (C:3), age ≥50 years (A:2), male sex (M:3) and platelet count
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
- Medical Data Analytics Centre (MDAC), The Chinese University of Hong Kong, Hong Kong, China.
- Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.
- Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Internal Medicine, Union Hospital, Hong Kong, China.
ORCID profiles: Hye Won Lee, Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong, Young-Suk Lim, Henry Lik-Yuen Chan, Sang Hoon Ahn, Grace Lai-Hung Wong, Jonggi Choi
Funding
- National Evidence-based Healthcare Collaborating Agency
- National R & D Program for Cancer Control
- National Research Foundation of Korea
- Ministry of Health and Welfare
Cite
APA
Lee, H. W., Yip, T. C., Wong, V. W., Lim, Y. S., Chan, H. L., Ahn, S. H., Wong, G. L., & Choi, J. (2024). CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17933
Vancouver
Lee HW, Yip TC, Wong VW, Lim YS, Chan HL, Ahn SH, et al. CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17933
BibTeX
@article{Lee2024,
author = {Lee, Hye Won and Yip, Terry Cheuk-Fung and Wong, Vincent Wai-Sun and Lim, Young-Suk and Chan, Henry Lik-Yuen and Ahn, Sang Hoon and Wong, Grace Lai-Hung and Choi, Jonggi},
title = {CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.17933}
}
EUVIMED